Literature DB >> 18220499

Alendronate for the treatment of osteoporosis in men.

W P Olszynski1, K S Davison.   

Abstract

BACKGROUND: Men have higher rates of osteoporosis and suffer fragility fractures more often than previously believed. Fracture-related morbidity and mortality in men is substantially higher than in women.
OBJECTIVE: To investigate alendronate for treating osteoporosis in men.
METHODS: Search limited to 'men' and 'English'; keywords were 'osteoporosis' or 'bone density' or 'fracture' and 'alendronate'. RESULTS/
CONCLUSIONS: Alendronate is an amino-bisphosphonate with proved efficacy for increasing bone mineral density in men with idiopathic or secondary osteoporosis and has demonstrated an ability to prevent vertebral fractures in men with low bone mass. There are trends for alendronate to decrease the risk of non-vertebral fracture, but larger trials are needed to conclusively establish this benefit. Alendronate is a well-tolerated and comparatively safe drug with an attractive once-a-week dosing regimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220499     DOI: 10.1517/14656566.9.3.491

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Analysis of daily teriparatide treatment for osteoporosis in men.

Authors:  R Niimi; T Kono; A Nishihara; M Hasegawa; A Matsumine; T Kono; A Sudo
Journal:  Osteoporos Int       Date:  2015-01-08       Impact factor: 4.507

2.  Bone-crack detection, targeting, and repair using ion gradients.

Authors:  Vinita Yadav; Jonathan D Freedman; Mark Grinstaff; Ayusman Sen
Journal:  Angew Chem Int Ed Engl       Date:  2013-08-26       Impact factor: 15.336

Review 3.  Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates.

Authors:  Blessing Aderibigbe; Isiaka Aderibigbe; Patricia Popoola
Journal:  Pharmaceutics       Date:  2016-12-26       Impact factor: 6.321

4.  Alendronate Release from UHMWPE-Based Biomaterials in Relation to Particle Size of the GUR Powder for Manufacturing.

Authors:  Michael Seidenstuecker; Julia Weber; Sergio H Latorre; Brigitte Straub; Ulrich Matthes; Christian Friedrich; Hermann O Mayr; Anke Bernstein
Journal:  Materials (Basel)       Date:  2019-06-06       Impact factor: 3.623

5.  Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.

Authors:  Anselm Mak; Mike W L Cheung; Roger Chun-Man Ho; Alicia Ai-Cia Cheak; Chak Sing Lau
Journal:  BMC Musculoskelet Disord       Date:  2009-09-21       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.